Kanal Singh, Kevin Rubenstein, Viviane Callier, Katy Shaw-Saliba, Adam Rupert, Robin Dewar, Sylvain Laverdure, Helene Highbarger, Perrine Lallemand, Meei-Li Huang, Keith R Jerome, Reigran Sampoleo, Margaret G Mills, Alexander L Greninger, Kavita Juneja, Danielle Porter, Constance A Benson, Walla Dempsey, Hana M El Sahly, Chris Focht, Nikolaus Jilg, Catharine I Paules, Rekha R Rapaka, Timothy M Uyeki, H Clifford Lane, John Beigel, Lori E Dodd
BACKGROUND: Although antivirals remain important for the treatment COVID-19, methods to assess treatment efficacy are lacking. Here, we investigated the impact of remdesivir on viral dynamics and their contribution to understanding antiviral efficacy in the multicenter ACTT-1 clinical trial that randomized patients to remdesivir or placebo. METHODS: Longitudinal specimens collected during hospitalization from a substudy of 642 COVID-19 patients were measured for viral RNA (upper respiratory tract and plasma), viral nucleocapsid antigen (serum), and host immunologic markers...
April 24, 2024: Journal of Infectious Diseases